New HIV vaccine combo shows promise in early safety trial
NCT ID NCT05182125
First seen Nov 01, 2025 · Last updated May 19, 2026 · Updated 26 times
Summary
This early-stage study tested two experimental HIV vaccines in 34 healthy, HIV-negative adults to see if they are safe and trigger an immune response. The vaccines use a harmless chimpanzee virus to deliver HIV proteins, followed by a protein boost. The goal is to gather safety data and measure antibody production, not to prevent HIV infection at this stage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Aurum Institute Klerksdorp CRS
Klerksdorp, South Africa
-
CAPRISA eThekwini CRS
Durban, South Africa
-
Emavundleni CRS
Cape Town, South Africa
-
Isipingo CRS
Isipingo, South Africa
-
Setshaba Research Centre CRS
Soshanguve, South Africa
-
Soweto HVTN CRS
Johannesburg, South Africa
Conditions
Explore the condition pages connected to this study.